{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:27:00Z","timestamp":1786602420809,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that leads to neurological disability, more pronounced in the progressive phase. Teriflunomide, an oral disease-modifying therapy, has shown potential neuroprotective effects beyond relapse reduction, including preservation of brain integrity and mitigation of disability progression. This review provides supportive evidence of the effects of teriflunomide on disability progression, cognition, and MRI markers of neurodegeneration in MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Embase, Scopus, and Web of Science were searched to identify relevant studies evaluating the effects of teriflunomide on disability progression, cognition, and MRI markers of neurodegeneration in MS such as brain volume loss. Clinical trials, extension studies, comparator studies, and real-world observational cohorts were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Teriflunomide demonstrated consistent effects stabilizing disability progression, maintaining cognitive performance, reducing brain volume loss and preserving gray and white matter integrity across multiple studies. Findings from various studies support its role in limiting disability progression. Proposed mechanisms include preservation of mitochondrial integrity, reduction of oxidative stress, and promotion of remyelination. Although higher-efficacy therapies may provide superior inflammatory control, teriflunomide may have an important role in the long-term management of MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Teriflunomide is emerging as a valuable, multi-faceted contributor to the MS treatment landscape, with data supporting its role in preserving brain volume, slowing disability progression, and maintaining cognitive function. Additionally, its favorable long-term tolerability and minimal immunocompromise effects further support its value as a therapeutic option over the longer course in PwMS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1882453","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:00Z","timestamp":1786599120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Progression-related outcomes of teriflunomide in multiple sclerosis clinical trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Farhad","family":"Mahmoudi","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Essentia Health Neurology, Duluth Clinic","place":["Duluth, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Flores Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Nittala","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kottil","family":"Rammohan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheline","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1093\/brain\/awae251","article-title":"The ageing central nervous system in multiple sclerosis: the imaging perspective","volume":"147","author":"Filippi","year":"2024","journal-title":"Brain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jns.2005.03.016","article-title":"Reduction of brain volume in MS. MRI and pathology findings","volume":"233","author":"Lycklama \u00e0 Nijeholt","year":"2005","journal-title":"J Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1038\/s41598-022-07024-7","article-title":"Teriflunomide shifts the astrocytic bioenergetic profile from oxidative metabolism to glycolysis and attenuates TNF\u03b1-induced inflammatory responses","volume":"12","author":"Kabiraj","year":"2022","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5563","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"11","author":"Klotz","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12974-022-02686-6","article-title":"Teriflunomide as a therapeutic means for myelin repair","volume":"20","author":"G\u00f6ttle","year":"2023","journal-title":"J Neuroinflammation"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e51260","DOI":"10.1002\/eji.202451260","article-title":"Teriflunomide inhibits human FOXP3(+) regulatory T cell function by interference with mitochondrial respiration","volume":"55","author":"Dyczko","year":"2025","journal-title":"Eur J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/cns.14150","article-title":"Dihydroorotate dehydrogenase regulates ferroptosis in neurons after spinal cord injury via the P53-ALOX15 signaling pathway","volume":"29","author":"Li","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","article-title":"Clinical relevance of brain volume measures in multiple sclerosis","volume":"28","author":"De Stefano","year":"2014","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13317-019-0117-5","article-title":"Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options","volume":"10","author":"Andravizou","year":"2019","journal-title":"Auto Immun Highlights"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12883-024-03888-6","article-title":"Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies","volume":"24","author":"Zivadinov","year":"2024","journal-title":"BMC Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"P3. 038","DOI":"10.1212\/wnl.86.16_supplement.p3.038","article-title":"Outcomes in patients with progressive MS: analysis of teriflunomide long-term extension data (P3. 038)","volume":"86","author":"Nelson","year":"2016","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458513475723","article-title":"Magnetic resonance imaging outcomes from a phase III trial of teriflunomide","volume":"19","author":"Wolinsky","year":"2013","journal-title":"Mult Scler"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1756286420970754","DOI":"10.1177\/1756286420970754","article-title":"Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS","volume":"13","author":"Zivadinov","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0143942","DOI":"10.1371\/journal.pone.0143942","article-title":"Grey matter atrophy in multiple sclerosis: clinical interpretation depends on choice of analysis method","volume":"11","author":"Popescu","year":"2016","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030344","article-title":"Effect of Teriflunomide and dimethyl fumarate on cortical atrophy and leptomeningeal inflammation in multiple sclerosis: a retrospective, observational, case-control pilot study","volume":"8","author":"Zivadinov","year":"2019","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"P6.334","DOI":"10.1212\/WNL.88.16_supplement.P6.334","article-title":"Evaluating the effect of teriflunomide on cortical gray matter atrophy in the phase 3 TOPIC study","volume":"88","author":"Zivadinov","year":"2017","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jns.2018.03.028","article-title":"Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures","volume":"388","author":"Zivadinov","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1177\/1352458519855722","article-title":"Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide","volume":"26","author":"Sprenger","year":"2020","journal-title":"Mult Scler"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40120-023-00557-7","article-title":"Effectiveness and safety of Teriflunomide in relapsing-remitting multiple sclerosis and improvements in quality of life: results from the Real-world TERICARE study","volume":"12","author":"Meca-Lallana","year":"2023","journal-title":"Neurol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"104472","DOI":"10.1016\/j.msard.2022.104472","article-title":"Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: a real-world retrospective multicenter analysis","volume":"70","author":"Berkovich","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","article-title":"Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial","volume":"80","author":"Lebrun-Fr\u00e9nay","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5471987","article-title":"Teriflunomide safety and efficacy in advanced progressive multiple sclerosis","volume":"2020","author":"Moreira Ferreira","year":"2020","journal-title":"Mult Scler Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","article-title":"Cognitive impairment in multiple sclerosis","volume":"7","author":"Chiaravalloti","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"623914","DOI":"10.3389\/fneur.2020.623914","article-title":"Thalamic injury and cognition in multiple sclerosis","volume":"11","author":"Amin","year":"2020","journal-title":"Front Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1177\/13524585221089534","article-title":"Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: post hoc analysis of the TEMSO core and extension studies","volume":"28","author":"Sprenger","year":"2022","journal-title":"Mult Scler"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1007\/s00415-023-11820-0","article-title":"Effectiveness of teriflunomide on no evidence of disease activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study","volume":"270","author":"Amato","year":"2023","journal-title":"J Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"105793","DOI":"10.1016\/j.msard.2024.105793","article-title":"Teriflunomide, cognition and MRI: a longitudinal study","volume":"90","author":"Pfaff","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00415-025-13221-x","article-title":"Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss multiple sclerosis cohort","volume":"272","author":"Cagol","year":"2025","journal-title":"J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2040622320944773","DOI":"10.1177\/2040622320944773","article-title":"Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations","volume":"11","author":"Malla","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031538","article-title":"Teriflunomide preserves neuronal activity and protects mitochondria in brain slices exposed to oxidative stress","volume":"23","author":"Malla","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1882453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:32:02Z","timestamp":1786599122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1882453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":41,"alternative-id":["10.3389\/fneur.2026.1882453"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1882453","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1882453"}}